The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles
Open accessAbstract
Oral drug absorption is a process influenced by the physicochemical and biopharmaceutical properties of the drug and its inter-relationship with the gastrointestinal tract. Drug solubility, dissolution and permeability across intestinal barrier are the key parameters controlling absorption. This review provides an overview of the factors that affect drug absorption and the classification of a drug on the basis of solubility and permeability. The biopharmaceutical classification system (BCS) was introduced in early 90׳s and is a regulatory tool used to predict bioavailability problems associated with a new entity, thereby helping in the development of a drug product. Strategies to combat solubility and permeability issues are also discussed. Bioavailability of a drug depends on physicochemical properties of the drug and physiological factors and dosage-related factors. Drug absorption occurs from the gut wall by passive diffusion, carrier-mediated uptake and paracellular transport. Several formulation strategies can be used to combat poor bioavailability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Block copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
Dressman, J. B., Amidon, G. L., Reppas, C., & Shah, V. P. (1998) · Pharmaceutical Research · doi:10.1023/a:1011984216775 · Cited by 1,097
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347
Montelukast-loaded nanostructured lipid carriers: Part I Oral bioavailability improvement
Patil-Gadhe, A., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.019 · Cited by 107
Self-citationChen, L., Wang, Y., Zhang, J., Hao, L., Guo, H., Lou, H., & Zhang, D. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.005 · Cited by 78
Sai, Y. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.91 · Cited by 60
Research works printed but not linked: 156
- Bergström, 2014, Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs, Eur J Pharm Sci, 57, 173, 10.1016/j.ejps.2013.10.015 · DOI · Paper page
- Dokoumetzidis, 2006, A century of dissolution research: from noyes and whitney to the biopharmaceutics classification system, Int J Pharm, 321, 1, 10.1016/j.ijpharm.2006.07.011 · DOI · Paper page
- Noyes, 1897, The rate of solution of solid substances in their own solutions, J Am Chem Soc, 19, 930, 10.1021/ja02086a003 · DOI · Paper page
- Brünner, 1904, Reaktionsgeschwindigkeit in heterogen systemen, Z Phys Chem, 47, 56, 10.1515/zpch-1904-4705 · DOI · Paper page
- Hixson, 1931, Dependence of reaction velocity upon surface and agitation, Ind Eng Chem, 23, 923, 10.1021/ie50260a018 · DOI · Paper page
- Danckwerts, 1951, Significance of liquid-film coefficients in gas absorption, Ind Eng Chem, 43, 1460, 10.1021/ie50498a055 · DOI · Paper page
- Higuchi, 1961, Rate of release of medicaments from ointment bases containing drugs in suspension, J Pharm Sci, 50, 874, 10.1002/jps.2600501018 · DOI · Paper page
- Brown, 2014, USP and dissolution—20 years of progress, Dissolut Technol, 2014, 24, 10.14227/DT210314P24 · doi:10.14227/dt210314p24
- Federation International Pharmaceutique, 1981, FIP guidelines for dissolution testing of solid oral products, Die Pharm Ind, 42, 334
- Dahan, 2009, Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs, AAPS J, 11, 740, 10.1208/s12248-009-9144-x · DOI · Paper page
- Martinez, 2002, A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals, J Clin Pharmacol, 42, 620, 10.1177/00970002042006005 · DOI · Paper page
- Pavurala, 2013, A mechanistic approach for modeling oral drug delivery, Comp Chem Eng, 57, 196, 10.1016/j.compchemeng.2013.06.002 · DOI
- Lennernäs, 1998, Human intestinal permeability, J Pharm Sci, 87, 403, 10.1021/js970332a · DOI · Paper page
- Yu, 1996, Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption, Adv Drug Deliv Rev, 19, 359, 10.1016/0169-409X(96)00009-9 · DOI · Paper page
- Azarmi, 2007, Current perspectives in dissolution testing of conventional and novel dosage forms, Int J Pharm, 328, 12, 10.1016/j.ijpharm.2006.10.001 · DOI · Paper page
- Alsenz, 2007, High throughput solubility measurement in drug discovery and development, Adv Drug Deliv Rev, 59, 546, 10.1016/j.addr.2007.05.007 · DOI · Paper page
- Noyes, 1987, The rate of solution of solid substances in their own solutions, J Am Chem Soc, 19, 930, 10.1021/ja02086a003 · DOI · Paper page
- Bansil, 2006, Mucin structure, aggregation, physiological functions and biomedical applications, Curr Opin Colloid Interface Sci, 11, 164, 10.1016/j.cocis.2005.11.001 · DOI · Paper page
- Behrens, 2001, Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells, Pharm Res, 18, 1138, 10.1023/A:1010974909998 · DOI · Paper page
- Smith, 1999, Pharmacokinetics and metabolism in early drug discovery, Curr Opin Chem Biol, 3, 373, 10.1016/S1367-5931(99)80056-8 · DOI · Paper page
- Lipka, 1996, Transmembrane transport of peptide type compounds: prospects for oral delivery, J Control Release, 39, 121, 10.1016/0168-3659(95)00145-X · doi:10.1016/0168-3659(95)00145-x
- Petri, 2006, Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers, Int J Clin Pharmacol Ther, 44, 71, 10.5414/CPP44071 · DOI
- Estudante, 2013, Intestinal drug transporters: an overview, Adv Drug Deliv Rev, 65, 1340, 10.1016/j.addr.2012.09.042 · DOI · Paper page
- Minuesa, 2011, Drug uptake transporters in antiretroviral therapy, Pharm Ther, 132, 268, 10.1016/j.pharmthera.2011.06.007 · DOI
- Kunta, 2004, Intestinal drug transporters: in vivo function and clinical importance, Curr Drug Metab, 5, 109, 10.2174/1389200043489144 · DOI
- Varma, 2006, Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery, Curr Opin Chem Biol, 10, 367, 10.1016/j.cbpa.2006.06.015 · DOI
- Curatolo, 1998, Physical chemical properties of oral drug candidates in the discovery and exploratory development settings, Pharm Sci Technol Today, 1, 387, 10.1016/S1461-5347(98)00097-2 · doi:10.1016/s1461-5347(98)00097-2
- Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J Pharmacol Toxicol Methods, 44, 235, 10.1016/S1056-8719(00)00107-6 · DOI · Paper page
- van de Waterbeemd, 2001, Property-based design: optimization of drug absorption and pharmacokinetics, J Med Chem, 44, 1313, 10.1021/jm000407e · DOI · Paper page
- Lipinski, 2004, Navigating chemical space for biology and medicine, Nature, 432, 855, 10.1038/nature03193 · DOI · Paper page
- Wenlock, 2003, A comparison of physiochemical property profiles of development and marketed oral drugs, J Med Chem, 46, 1250, 10.1021/jm021053p · DOI · Paper page
- Palm, 1997, Polar molecular surface properties predict the intestinal absorption of drugs in humans, Pharm Res, 14, 568, 10.1023/A:1012188625088 · DOI · Paper page
- Clark, 1999, Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption, J Pharm Sci, 88, 807, 10.1021/js9804011 · DOI · Paper page
- Ritchie, 2009, The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design?, Drug Discov Today, 14, 1011, 10.1016/j.drudis.2009.07.014 · DOI · Paper page
- Dressman, 1985, Absorption potential: estimating the fraction absorbed for orally administered compounds, J Pharm Sci, 74, 588, 10.1002/jps.2600740523 · DOI · Paper page
- Yalkowsky, 2006, A ‘rule of unity’ for human intestinal absorption, Pharm Res, 23, 2475, 10.1007/s11095-006-9000-y · doi:10.1007/s11095-006-9000-y
- Fleisher, 1999, Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications, Clin Pharmacokinet, 36, 233, 10.2165/00003088-199936030-00004 · DOI · Paper page
- Freire, 2011, Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery, Int J Pharm, 415, 15, 10.1016/j.ijpharm.2011.04.069 · DOI · Paper page
- Avdeef, 2001, Physicochemical profiling (solubility, permeability and charge state), Curr Top Med Chem, 1, 277, 10.2174/1568026013395100 · DOI · Paper page
- Kimura, 2002, Gastrointestinal transit and drug absorption, Biol Pharm Bull, 25, 149, 10.1248/bpb.25.149 · DOI · Paper page
- Fujioka, 2008, Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug, Int J Pharm, 352, 36, 10.1016/j.ijpharm.2007.10.008 · DOI
- Cook, 2002, An industrial implementation of the biopharmaceutics classification system, Dissolut Technol, 9, 6, 10.14227/DT090202P6 · doi:10.14227/dt090202p6
- Cook, 2010, Impact of biopharmaceutics classification system-based biowaivers, Mol Pharm, 7, 1539, 10.1021/mp1001747 · DOI
- Sakore, 2011, In vitro–in vivo correlation (IVIVC): a strategic tool in drug development, J Bioequiv Availab, 2011, S3
- Batchelor, 2013, Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients, Eur J Pharm Biopharm, 85, 833, 10.1016/j.ejpb.2013.04.015 · DOI
- Alelyunas, 2009, Application of a dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates, Eur J Pharm Sci, 37, 172, 10.1016/j.ejps.2009.02.007 · DOI
- Saal, 2012, Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks, Eur J Pharm Sci, 47, 589, 10.1016/j.ejps.2012.07.019 · DOI
- Zhou, 2007, Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery, J Pharm Sci, 96, 3052, 10.1002/jps.20913 · DOI
- Hörter, 1997, Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv Drug Deliv Rev, 25, 3, 10.1016/S0169-409X(96)00487-5 · DOI · Paper page
- Lue, 2008, Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound, Eur J Pharm Biopharm, 69, 648, 10.1016/j.ejpb.2007.12.013 · DOI
- Klein, 2010, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS J, 12, 397, 10.1208/s12248-010-9203-3 · DOI · Paper page
- Aiache, 1997, FIP guidelines for dissolution testing of solid oral products, Dissolut Technol, 4, 5, 10.14227/DT040497P5 · DOI
- Wei, 2006, Biorelevant dissolution media as a predictive tool for glyburide a class II drug, Eur J Pharm Sci, 29, 45, 10.1016/j.ejps.2006.05.004 · DOI
- Lehto, 2011, Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs, Eur J Pharm Biopharm, 78, 531, 10.1016/j.ejpb.2011.02.007 · DOI
- Tsume, 2013, Dissolution effect of gastric and intestinal pH fora BCS class II drug, pioglitazone: new in vitro dissolution system to predict in vivo dissolution, J Bioequiv Availab, 5, 224, 10.4172/jbb.1000162 · doi:10.4172/jbb.1000162
- Motz, 2007, Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell, Eur J Pharm Biopharm, 66, 286, 10.1016/j.ejpb.2006.10.015 · DOI
- Zakeri-Milani, 2009, Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability, Eur J Pharm Biopharm, 73, 102, 10.1016/j.ejpb.2009.04.015 · DOI
- Muenster, 2011, Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions, Eur J Pharm Biopharm, 78, 522, 10.1016/j.ejpb.2011.01.023 · DOI
- Lennernäs, 2014, Human in vivo regional intestinal permeability: importance for pharmaceutical drug development, Mol Pharm, 11, 12, 10.1021/mp4003392 · DOI
- Lennernäs, 2013, Regional intestinal drug permeation: biopharmaceutics and drug development, Eur J Pharm Sci, 57, 333, 10.1016/j.ejps.2013.08.025 · DOI · Paper page
- Wahlang, 2011, Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model, Eur J Pharm Biopharm, 77, 275, 10.1016/j.ejpb.2010.12.006 · DOI · Paper page
- Blume, 1999, The biopharmaceutics classification system (BCS): class III drugs—better candidates for BA/BE waiver?, Eur J Pharm Sci, 9, 117, 10.1016/S0928-0987(99)00076-7 · DOI
- Tsume, 2014, The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC, Eur J Pharm Sci, 57, 152, 10.1016/j.ejps.2014.01.009 · DOI · Paper page
- Custodio, 2008, Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption, Adv Drug Deliv Rev, 60, 717, 10.1016/j.addr.2007.08.043 · DOI · Paper page
- Shah, 2011, Recent advances and novel strategies in pre-clinical formulation development: an overview, J Control Release, 156, 281, 10.1016/j.jconrel.2011.07.003 · DOI
- Rabinow, 2004, Nanosuspensions in drug delivery, Nat Rev Drug Discov, 3, 785, 10.1038/nrd1494 · DOI · Paper page
- Basavaraj, 2014, Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges, Acta Pharm Sin B, 4, 3, 10.1016/j.apsb.2013.12.003 · DOI
- Desai, 2012, Overcoming poor oral bioavailability using nanoparticle formulations—opportunities and limitations, Drug Discov Today, 9, e87, 10.1016/j.ddtec.2011.12.001 · DOI · Paper page
- Huang, 2014, Fundamental aspects of solid dispersion technology for poorly soluble drugs, Acta Pharm Sin B, 4, 18, 10.1016/j.apsb.2013.11.001 · DOI · Paper page
- Vo, 2013, Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs, Eur J Pharm Biopharm, 85, 799, 10.1016/j.ejpb.2013.09.007 · DOI · Paper page
- Blagden, 2007, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv Drug Deliv Rev, 59, 617, 10.1016/j.addr.2007.05.011 · DOI · Paper page
- Elder, 2013, Use of pharmaceutical salts and cocrystals to address the issue of poor solubility, Int J Pharm, 453, 88, 10.1016/j.ijpharm.2012.11.028 · doi:10.1016/j.ijpharm.2012.11.028
- Semalty, 2014, Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: a critical and meta-analysis, Expert Opin Drug Deliv, 11, 1255, 10.1517/17425247.2014.916271 · DOI
- Brewster, 2007, Cyclodextrins as pharmaceutical solubilizers, Adv Drug Deliv Rev, 59, 645, 10.1016/j.addr.2007.05.012 · DOI · Paper page
- Mu, 2013, Lipid-based formulations for oral administration of poorly water-soluble drugs, Int J Pharm, 453, 215, 10.1016/j.ijpharm.2013.03.054 · DOI · Paper page
- Chen, 2011, Nanonization strategies for poorly water-soluble drugs, Drug Discov Today, 16, 354, 10.1016/j.drudis.2010.02.009 · DOI · Paper page
- Dinarvand, 2015, Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer, Int J Biol Macromol, 78, 112, 10.1016/j.ijbiomac.2015.03.066 · doi:10.1016/j.ijbiomac.2015.03.066
- Kharia, 2015, Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach, J Microencapsul, 32, 521, 10.3109/02652048.2015.1010457 · doi:10.3109/02652048.2015.1010457
- Sharma, 2015, Investigating the role of pluronic-g-cationic polyelectrolyte as functional stabilizer for nanocrystals: impact on paclitaxel oral bioavailability and tumor growth, Acta Biomater, 26, 169, 10.1016/j.actbio.2015.08.005 · DOI
- Gadadare, 2015, Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior, AAPS PharmSciTech, 16, 787, 10.1208/s12249-014-0267-8 · DOI
- Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv Drug Deliv Rev, 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
- Durán-Lobato, 2014, Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles, J Biomed Nanotechnol, 10, 1068, 10.1166/jbn.2014.1806 · DOI
- Chellampillai, 2011, Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles, Eur J Drug Metab Pharmacokinet, 35, 123, 10.1007/s13318-010-0016-7 · DOI
- Cho, 2010, Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives, Int J Pharm, 396, 91, 10.1016/j.ijpharm.2010.06.016 · doi:10.1016/j.ijpharm.2010.06.016
- Dalvi, 2013, Precipitation and stabilization of ultrafine particles of Fenofibrate in aqueous suspensions by RESOLV, Powder Technol, 236, 75, 10.1016/j.powtec.2012.05.038 · DOI
- Bege, 2013, In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm, Eur J Pharm Biopharm, 84, 99, 10.1016/j.ejpb.2012.12.016 · doi:10.1016/j.ejpb.2012.12.016
- Zhang, 2013, Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement, Eur J Pharm Sci, 48, 740, 10.1016/j.ejps.2012.12.026 · doi:10.1016/j.ejps.2012.12.026
- Angi, 2014, Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties, Eur J Pharm Biopharm, 86, 361, 10.1016/j.ejpb.2013.10.004 · DOI
- Saremi, 2013, Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies, Biomed Res Int, 2013, 150478, 10.1155/2013/150478 · DOI
- Tam, 2015, AH. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery, Colloids Surf B Biointerfaces, 139, 249, 10.1016/j.colsurfb.2015.12.026 · DOI
- Liu, 2015, Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation, Int J Nanomed, 10, 6425, 10.2147/IJN.S87143 · DOI
- Ahuja, 2015, Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension, Int J Pharm, 478, 540, 10.1016/j.ijpharm.2014.12.003 · DOI
- Quan, 2012, A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability, Int J Pharm, 430, 366, 10.1016/j.ijpharm.2012.04.025 · doi:10.1016/j.ijpharm.2012.04.025
- Onoue, 2013, In vitro/in vivo characterization of nanocrystalline formulation of tranilast with improved dissolution and hepatoprotective properties, Eur J Pharm Biopharm, 85, 952, 10.1016/j.ejpb.2013.09.003 · doi:10.1016/j.ejpb.2013.09.003
- Nkansah, 2013, Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs, J Control Release, 169, 150, 10.1016/j.jconrel.2013.03.032 · doi:10.1016/j.jconrel.2013.03.032
- Yoshida, 2012, Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: evaluation of solid dispersion formulations, Int J Pharm, 428, 18, 10.1016/j.ijpharm.2012.02.041 · DOI
- Choudhary, 2012, Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability, Acta Pharm Sin B, 2, 421, 10.1016/j.apsb.2012.05.002 · DOI
- Visser, 2010, Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240, Eur J Pharm Biopharm, 74, 233, 10.1016/j.ejpb.2009.10.004 · doi:10.1016/j.ejpb.2009.10.004
- Shi, 2013, Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions, Powder Technol, 247, 211, 10.1016/j.powtec.2013.06.039 · DOI
- Kawabata, 2010, Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability, Eur J Pharm Sci, 39, 256, 10.1016/j.ejps.2009.12.009 · DOI
- Mora, 2013, Characterization, dissolution and in vivo evaluation of solid acetazolamide complexes, Carbohydr Polym, 98, 380, 10.1016/j.carbpol.2013.06.012 · DOI
- Mennini, 2014, Physico-chemical characterization in solution and in the solid state of clonazepam complexes with native and chemically-modified cyclodextrins, J Pharm Biomed Anal, 89, 142, 10.1016/j.jpba.2013.11.009 · DOI
- Salústio, 2012, Release profile of ibuprofen in β-cyclodextrin complexes from two different solid dosage forms, Powder Technol, 221, 245, 10.1016/j.powtec.2012.01.008 · doi:10.1016/j.powtec.2012.01.008
- Miao, 2016, Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state, Drug Dev Ind Pharm, 42, 1234, 10.3109/03639045.2015.1118496 · DOI
- Zhang, 2012, Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery, Int J Pharm, 427, 337, 10.1016/j.ijpharm.2012.02.013 · DOI
- Christiansen, 2014, Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano emulsifying drug delivery system (SNEDDS), Eur J Pharm Sci, 57, 164, 10.1016/j.ejps.2013.11.003 · DOI
- Elgart, 2013, Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol, Pharm Res, 30, 3029, 10.1007/s11095-013-1063-y · DOI
- Bajaj, 2013, Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate, Drug Dev Ind Pharm, 39, 635, 10.3109/03639045.2012.683440 · DOI
- Beg, 2012, Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers, AAPS PharmSciTech, 13, 1416, 10.1208/s12249-012-9865-5 · doi:10.1208/s12249-012-9865-5
- Miao, 2015, Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect, Drug Deliv, 21, 1
- Hyma, 2013, Formulation and characterisation of self-microemulsifying drug delivery system of pioglitazone, Biomed Prev Nutr, 3, 345, 10.1016/j.bionut.2013.09.005 · doi:10.1016/j.bionut.2013.09.005
- Kalhapure, 2012, Akamanchi. Oleic acid based heterolipid synthesis, characterization and application in self-microemulsifying drug delivery system, Int J Pharm, 425, 9, 10.1016/j.ijpharm.2012.01.004 · DOI
- Liu, 2012, Preparation and evaluation of self-microemulsifying drug delivery system of baicalein, Fitoterapia, 83, 1532, 10.1016/j.fitote.2012.08.021 · DOI
- Videira, 2013, Experimental design towards an optimal lipid nanosystem: a new opportunity for paclitaxel-based therapeutics, Eur J Pharm Sci, 49, 302, 10.1016/j.ejps.2013.03.005 · DOI
- Beloqui, 2013, Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier, J Control Release, 166, 115, 10.1016/j.jconrel.2012.12.021 · DOI · Paper page
- Sanganwar, 2008, Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide, Int J Pharm, 360, 213, 10.1016/j.ijpharm.2008.04.041 · DOI
- Ambrogi, 2012, MCM-41 for furosemide dissolution improvement, Microp Mesop Mater, 147, 343, 10.1016/j.micromeso.2011.07.007 · DOI
- Ambrogi, 2007, Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate, Eur J Pharm Sci, 32, 216, 10.1016/j.ejps.2007.07.005 · DOI
- Mellaerts, 2008, Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica, Eur J Pharm Biopharm, 69, 223, 10.1016/j.ejpb.2007.11.006 · DOI · Paper page
- Salonen, 2005, Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs, J Control Release, 108, 362, 10.1016/j.jconrel.2005.08.017 · DOI · Paper page
- Chen, 2015, Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles, Int J Nanomed, 10, 7265
- Dahmani, 2012, Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation, Eur J Pharm Sci, 47, 179, 10.1016/j.ejps.2012.05.015 · DOI
- Smith, 2011, Cocrystals of quercetin with improved solubility and oral bioavailability, Mol Pharm, 8, 1867, 10.1021/mp200209j · DOI · Paper page
- Basavoju, 2008, Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization, Pharm Res, 25, 530, 10.1007/s11095-007-9394-1 · doi:10.1007/s11095-007-9394-1
- Évora, 2014, A thermodynamic based approach on the investigation of a diflunisal pharmaceutical co-crystal with improved intrinsic dissolution rate, Int J Pharm, 466, 68, 10.1016/j.ijpharm.2014.02.048 · doi:10.1016/j.ijpharm.2014.02.048
- Soares, 2014, Evaluation of analytical tools and multivariate methods for quantification of co-former crystals in ibuprofen-nicotinamide co-crystals, J Pharm Biomed Anal, 89, 166, 10.1016/j.jpba.2013.11.005 · DOI
- Mulye, 2012, Improvement in physicochemical properties of ezetimibe using a crystal engineering technique, Powder Technol, 222, 131, 10.1016/j.powtec.2012.02.020 · doi:10.1016/j.powtec.2012.02.020
- Sadekar, 2013, Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin, Int J Pharm, 456, 175, 10.1016/j.ijpharm.2013.07.071 · DOI
- Gupta, 2007, Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes, J Pharm Pharm Sci, 10, 358
- Cheng, 2005, Polyamidoamine dendrimers used as solubility enhancers of ketoprofen, Eur J Med Chem, 40, 1390, 10.1016/j.ejmech.2005.08.002 · DOI
- Yáñez, 2011, Intestinal lymphatic transport for drug delivery, Adv Drug Deliv Rev, 63, 923, 10.1016/j.addr.2011.05.019 · DOI · Paper page
- Carrière, 2016, Impact of gastrointestinal lipolysis on oral lipid based formulations and bioavailability of lipophilic drugs, Biochimie, 125, 297, 10.1016/j.biochi.2015.11.016 · DOI
- Pouton, 2006, Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur J Pharm Sci, 29, 278, 10.1016/j.ejps.2006.04.016 · DOI · Paper page
- Kumar, 2011, Nonionic surfactant vesicular systems for effective drug delivery-an overview, Acta Pharm Sin B, 1, 208, 10.1016/j.apsb.2011.09.002 · DOI · Paper page
- Pandita, 2014, Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol, Food Res Int, 62, 1165, 10.1016/j.foodres.2014.05.059 · DOI · Paper page
- Das, 2011, Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech, 12, 62, 10.1208/s12249-010-9563-0 · DOI · Paper page
- Iqbal, 2012, Nanostructured lipid carriers system: recent advances in drug delivery, J Drug Target, 20, 813, 10.3109/1061186X.2012.716845 · DOI · Paper page
- Chiou, 1971, Pharmaceutical applications of solid dispersion systems, J Pharm Sci, 60, 1281, 10.1002/jps.2600600902 · DOI · Paper page
- van der Mooter, 2012, The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate, Drug Discov Today, 9, e79, 10.1016/j.ddtec.2011.10.002 · DOI · Paper page
- Good, 2009, Solubility advantage of pharmaceutical cocrystals, Cryst Growth Des, 9, 2252, 10.1021/cg801039j · DOI · Paper page
- Jayasankar, 2010, Transformation pathways of cocrystal hydrates when coformer modulates water activity, J Pharm Sci, 99, 3977, 10.1002/jps.22245 · doi:10.1002/jps.22245
- Sanphui, 2012, Pharmaceutical cocrystals of niclosamide, Cryst Growth Des, 12, 4588, 10.1021/cg300784v · DOI
- McNamara, 2006, Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharm Res, 23, 1888, 10.1007/s11095-006-9032-3 · DOI · Paper page
- Vig, 2013, Amino acids as promoieties in prodrug design and development, Adv Drug Deliv Rev, 65, 1370, 10.1016/j.addr.2012.10.001 · DOI
- Rodriguez-Aller, 2013, In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application, J Control Release, 170, 153, 10.1016/j.jconrel.2013.04.019 · DOI
- Li, 2014, A macromolecular prodrug strategy for combinatorial drug delivery, J Colloid Interface Sci, 417, 301, 10.1016/j.jcis.2013.11.061 · DOI
- Falcoz, 2002, Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers, J Clin Pharmacol, 42, 887, 10.1177/009127002401102803 · doi:10.1177/009127002401102803
- Vierling, 2003, Prodrugs of HIV protease inhibitors, Curr Pharm Des, 9, 1755, 10.2174/1381612033454441 · DOI
- Bimbo, 2010, Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats, ACS Nano, 4, 3023, 10.1021/nn901657w · DOI · Paper page
- Wang, 2010, Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs, Mol Pharmacol, 7, 227, 10.1021/mp900221e · DOI
- Kapoor, 2009, Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release, J Control Release, 140, 34, 10.1016/j.jconrel.2009.07.015 · doi:10.1016/j.jconrel.2009.07.015
- Zhang, 2011, Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties, Int J Pharm, 410, 118, 10.1016/j.ijpharm.2010.07.040 · DOI
- Cao, 2013, Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs, Eur J Pharm Sci, 48, 64, 10.1016/j.ejps.2012.10.012 · DOI
- Chen, 2012, Mesoporous silica nanoparticles with manipulated microstructures for drug delivery, Colloids Surf B Biointerfaces, 95, 274, 10.1016/j.colsurfb.2012.03.012 · DOI
- Korotcenkov, 2010, Silicon porosification: state of the art, Crit Rev Solid State Mater Sci, 35, 153, 10.1080/10408436.2010.495446 · doi:10.1080/10408436.2010.495446
- Xu, 2013, Mesoporous systems for poorly soluble drugs, Int J Pharm, 453, 181, 10.1016/j.ijpharm.2012.09.008 · DOI · Paper page
Cited by
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. (2022) · Biomedicines · doi:10.3390/biomedicines10092055 · Cited by 704
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Bayón-Cordero, L., Alkorta, I., & Arana, L. (2019) · Nanomaterials · doi:10.3390/nano9030474 · Cited by 344
Zhang, X., Xing, H., Zhao, Y., & Ma, Z. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030074 · Cited by 285
Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles
Tao, J., Chow, S. F., & Zheng, Y. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.001 · Cited by 232
Johnson, S. L., Kirk, R. D., DaSilva, N. A., Ma, H., Seeram, N. P., & Bertin, M. J. (2019) · Metabolites · doi:10.3390/metabo9040078 · Cited by 101
Metadata
- Authors
- B. Shekhawat, P., & B. Pokharkar, V.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 7
- Issue
- 3
- Pages
- 260-280
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2547622589
- Cited by
- 176
- References
- 13
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Women Scientist Scheme-A (SR/WOS-A/LS-248/2012)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.